MAI Capital Management’s Integra LifeSciences IART Stock Holding History

MAI Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-62	Closed	-$585	–	3288
2026 Q1	$585	Buy	+62	New	+$681	﹤0.01%	4362
2025 Q4	–	Sell	-69	Closed	-$989	–	4409
2025 Q3	$989	Hold	69	–	–	﹤0.01%	3501
2025 Q2	$847	Sell	69 -7	-9%	-$102	﹤0.01%	3665
2025 Q1	$1.67K	Sell	76 -61	-45%	-$1.43K	﹤0.01%	3009
2024 Q4	$3.11K	Buy	+137	New	+$2.99K	﹤0.01%	2925

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

MAI Capital Management's IART Position: Q2 2026 in Review

MAI Capital Management sold out of Integra LifeSciences (IART) in Q2 2026, closing a stake of 62 shares — an estimated $585 sold.

MAI Capital Management first reported a position in IART in Q4 2024 and held it in 5 quarters. The position peaked at $3.11K in Q4 2024. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

MAI Capital Management reported no remaining Integra LifeSciences position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 62 Integra LifeSciences shares in Q2 2026, an estimated $585.
MAI Capital Management first reported a position in Integra LifeSciences in Q4 2024 and held it in 5 quarters.
MAI Capital Management's Integra LifeSciences position peaked at $3.11K in Q4 2024.
212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.